Author

Steve Kornblau

U.T. M. D. Anderson Cancer Center - Cited by 38,748 - proteomics

Biography

Steve Kornblau is a well-known researcher working in Department of Leukemia, University of Texas MD Anderson Cancer Center and has extended valuable service for many years and has been a recipient of many awards and grants.  
Title
Cited by
Year
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse
NJ Short, H Kantarjian, F Ravandi, M Konopleva, N Jain, ...Blood Advances 6 (13), 4006-4014, 202
22
2022
Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia
CD DiNardo, CA Lachowiez, K Takahashi, S Loghavi, T Kadia, N Daver, ...American journal of hematology 97 (8), 1035-1043, 2022202
18
2022
Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia
N Baran, A Lodi, Y Dhungana, S Herbrich, M Collins, S Sweeney, ...Nature communications 13 (1), 2801, 2022202
14
2022
The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemness
GE Thomas, G Egan, L García-Prat, A Botham, V Voisin, PS Patel, ...Nature cell biology 24 (6), 872-884, 2022202
12
2022
Updated phase IIb results of Venetoclax with FLAG-IDA in relapsed or refractory acute myeloid leukemia
SP Desikan, M Konopleva, K Takahashi, CA Lachowiez, S Loghavi, ...Blood 140 (Supplement 1), 54-56, 2022202
3
2022
Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets
TL Griffen, FW Hoff, Y Qiu, JW Lillard Jr, A Ferrajoli, P Thompson, E Toro, ...Blood cancer journal 12 (), 4, 2022202
3
2022
Phase 2 study of ASTX727 (cedazuridine/decitabine) plus venetoclax (ven) in patients with relapsed/refractory acute myeloid leukemia (AML) or previously untreated, elderly …
F Ravandi, T Abuasab, Y Alvarado Valero, GC Issa, R Islam, NJ Short, ...Journal of Clinical Oncology 40 (16_suppl), 707-707, 2022202
3
2022
Heterogeneous nuclear ribonucleoprotein K is overexpressed in acute myeloid leukemia and causes myeloproliferation in mice via altered Runx1 splicing
MJL Aitken, P Malaney, X Zhang, SM Herbrich, L Chan, O Benitez, ...NAR cancer 4 (4), zcac09, 2022202
3
2022
Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF‐κB subunit RelA
AD van Dijk, FW Hoff, Y Qiu, RB Gerbing, AS Gamis, R Aplenc, EA Kolb, ...PROTEOMICS–Clinical Applications 16 (2), 2100072, 2022202
3
2022
S127: QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA-A PHASE I/II STUDY
S127: QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT-ITD MUTATED ACUTE MYELOID LEUKEMIA-A PHASE I/II STUDYM Yilmaz, M Muftuoglu, H Kantarjian, C DiNardo, T Kadia, G Borthakur, ...HemaSphere 6, 28-29, 2022202
3
2022
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT‐PCR for BCR::ABL1
NJ Short, E Jabbour, W Macaron, F Ravandi, N Jain, ...American journal of hematology, 030
2
2023
Microsatellite instability assessment by immunohistochemistry in acute myeloid leukemia: a reappraisal and review of the literature
S El Hussein, N Daver, JL Liu, S Kornblau, H Fang, S Konoplev, ...Clinical Lymphoma Myeloma and Leukemia (6), e386-e391, 0
2
2022
P371: hyper-CVAD with sequential blinatumomab, with or without inotuzumab ozogamicin, in adults with newly diagnosed philadelphia chromosome-negative B-cell acute lymphoblastic …
N Short, H Kantarjian, F Ravandi, M Yilmaz, T Kadia, P Thompson, ...HemaSphere 6, 71-7, 0
2
2022
P576: a Phase I/Ii study of milademetan (Ds3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia
P576: a Phase I/Ii study of milademetan (Ds303b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemiaJ Senapati, J Ishizawa, HA Abbas, S Loghavi, G Borthakur, GC Issa, ...HemaSphere 6, 475-476, 0
2
2022
Mechanisms of MCL-1 protein stability induced by MCL-1 antagonists in B-cell malignancies
SI Tantawy, A Sarkar, S Hubner, Z Tan, WG Wierda, A Eldeib, S Zhang, ...Clinical Cancer Research 9 (), 446-457, 030
2
2023
Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic …
PK Reville, H Kantarjian, G Borthakur, M Yilmaz, N Daver, N Short, ...Blood 140 (Supplement 1), 170-1704, 0
2
2022
S104: RBPs dysregulation cause hyper-nucleoli and ribosome gain-of-function driving bone marrow failure
S04: RBPs dysregulation cause hyper-nucleoli and ribosome gain-of-function driving bone marrow failureP Aguilar-Garrido, M Velasco, MH Sánchez, MÁN Aguadero, P Malaney, ...HemaSphere 6, 5-6, 2022202
1
2022
Protein profiling by reverse phase protein array (RPPA) in classical hairy cell leukemia (HCL) and HCL‐variant
FW Hoff, TL Griffen, Y Qiu, SM KornblauEJHaem 3 (4), 32-325, 2022202
1
2022
First in human study of anti-viral veto cells enabling successful engraftment without severe Gvhd in non-myeloablative T cell depleted haploidentical hematopoietic stem cell …
RE Champlin, E Bachar Lustig, Q Bashir, B Oran, SM Kornblau, C Hosing, ...Blood 40 (Supplement ), 220-222, 2022202
1
2022
The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated …
N Short, E Jabbour, F Ravandi, M Yilmaz, TM Kadia, PA Thompson, ...Blood 40 (Supplement ), 8966-8968, 2022202
1
2022

Referred From: https://scholar.google.com/citations?user=1FQYWTsAAAAJ&hl=en

Cited by
Citations 38748
h-index 100
i10-index 329
Recommended Journals
Open Access Journals